Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year High – Here’s What Happened

Avalyn Pharma Inc. (NASDAQ:AVLN) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $40.17 and last traded at $38.86, with a volume of 194791 shares. The stock had previously closed at $38.25.

Analyst Ratings Changes

Several analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company. Wall Street Zen cut shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings began coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating for the company. Guggenheim initiated coverage on Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Finally, Zacks Research raised Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Avalyn Pharma Trading Down 4.7%

The stock has a market capitalization of $1.65 billion and a P/E ratio of -1.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The stock’s 50 day simple moving average is $30.94.

Avalyn Pharma (NASDAQ:AVLN) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.05. As a group, sell-side analysts forecast that Avalyn Pharma Inc. will post -3.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Avalyn Pharma

An institutional investor recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp purchased a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma at the end of the most recent reporting period.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.